AMPH

Amphastar Pharmaceuticals, Inc. (AMPH) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company operates as a single reportable segment: pharmaceutical products.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2026 revenue increased 5% year-over-year, driven by new product launches (Ipratropium bromide, Iron sucrose, Teriparatide) and increased API sales. This offset declines in Glucagon (-42% Q2) and BAQSIMI (-3% Q2) due to pricing pressure and competition.
• Profitability Decline: Net income decreased 2% in Q2 and 35% YTD compared to the prior year. The YTD decline is primarily attributed to a significant decrease in Glucagon sales and higher operating expenses.
• Expense Increases: Operating expenses rose 21% YTD. Selling, distribution, and marketing expenses increased due to freight and BAQSIMI marketing. General and administrative expenses rose due to legal fees and ERP implementation. R&D expenses increased 22% YTD, driven by clinical trials for insulin and inhalation candidates.
• Balance Sheet Impact: Working capital decreased by $110.1 million to $367.8 million, largely due to a $100 million milestone payment liability accrued for BAQSIMI sales.

Guidance, Outlook, and Risks

• BAQSIMI Milestone: The company achieved the first annual net sales milestone of $175.0 million for BAQSIMI in June 2026, triggering a $100.0 million payment to Eli Lilly due in Q3 2026. This amount has been capitalized as an increase to intangible assets and PP&E.
• Regulatory Risk (FDA Warning Letter): In July 2026, the subsidiary IMS received an FDA Warning Letter regarding cGMP violations at its South El Monte, CA facility. While product distribution is not halted, the company is implementing remediation plans which may temporarily impact production capacity and increase manufacturing costs.
• Product Outlook: Management anticipates continued declines in Glucagon sales due to competition. Sales of Epinephrine and other products are expected to fluctuate based on competitor supply constraints.
• Liquidity: The company maintains $223.6 million in cash and cash equivalents. Management believes current resources and operating cash flows are sufficient to fund operations for the next 12 months.
• Share Repurchases: The company repurchased 3.7 million shares for $74.2 million during the first six months of 2026. As of June 30, 2026, approximately $0.4 million remained available under the current authorization.

Investor Verification Checklist

• Verify the impact of the IMS FDA Warning Letter on future production schedules and potential cost increases for remediation.
• Monitor the BAQSIMI sales trajectory to assess the likelihood of triggering the remaining $350 million in potential milestone payments to Eli Lilly.
• Review the Glucagon product line performance given the significant year-over-year revenue decline and competitive shift to ready-to-use formats.
• Assess the share pledging risk involving executive officers (Drs. Zhang and Luo), where significant portions of their holdings are pledged as collateral for loans, creating potential for forced sales if stock prices decline.
• Confirm the timing of the $100 million milestone payment to Eli Lilly in Q3 2026 and its impact on quarterly cash flow.